Drug Discovery

GTx, Oncternal Therapeutics sign merger deal to create new clinical-stage oncology firm

Biopharmaceutical firm GTx has entered into a merger agreement with clinical-stage biotechnology firm Oncternal Therapeutics to create a new a publicly-traded and clinical-stage oncology company.

Beam Therapeutics secures $135m funds to expand pipeline of precision genetic medicines

Beam Therapeutics, a biotechnology company developing precision genetic medicines through base editing, announced the successful completion of a $135m Series B financing.

GeoVax, Leidos expand collaboration to malaria vaccines

GeoVax Labs, a biotechnology company developing human vaccines, has expanded its collaboration activities with Leidos, to develop malaria vaccine candidates.

Biogen to acquire UK-based Nightstar Therapeutics for $877m

American multinational biotechnology company Biogen has agreed to acquire UK-based clinical-stage gene therapy firm Nightstar Therapeutics in a deal valued at around $877m.

Abpro, NJCTTQ partner to develop multiple bispecific antibody therapies

Abpro, a biotechnology company dedicated to developing next-generation antibody therapeutics to improve the lives of patients with severe and life-threatening diseases, and NJCTTQ, a global pharmaceutical company, have entered into an agreement to develop multiple novel bispecific antibody therapies in immuno-oncology, including best-in -class T-cell engagers.

Maze Therapeutics launches with $191m financing

Third Rock Ventures, a healthcare venture firm focused on disruptive areas of science and medicine, has launched Maze Therapeutics to focus on translating genetic insights into new medicines.

Axial Biotherapeutics raises $25m in Series B financing

Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative and neuropsychiatric diseases, announced the completion of a $25m series B equity financing.

Anthos Therapeutics launched to advance targeted therapies for cardiovascular disease

Novartis and Blackstone Life Sciences have launched new biopharmaceutical firm, dubbed Anthos Therapeutics, to develop new medicines for cardiovascular disease.

Imbrium, TetraGenetics announce research collaboration and license option to develop biologic therapeutics for pain

Imbrium Therapeutics, a clinical-stage biopharmaceutical company and operating subsidiary of Purdue Pharma, and TetraGenetics, a biotech company developing novel therapeutics for pain indications and autoimmune diseases, announced a strategic research & development collaboration to utilize TetraGenetics’ antibody discovery technology platform (TetraExpress) in the discovery and development of non-opioid biologic therapies for the treatment of chronic pain.